PureTech Announces Participation in Two Upcoming Investor Conferences
15 November 2021 - 11:00PM
Business Wire
Company to participate in fireside chats at
Piper Sandler Healthcare Conference and Evercore ISI HealthCONx
Conference
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the
“Company”), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announced that members of
the management team will participate in fireside chats at the
following upcoming investor conferences. Webcasts of the
presentations will be available at
https://investors.puretechhealth.com/events-presentations.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20211115005239/en/
Members of PureTech’s management team
will participate in fireside chats at the Piper Sandler 33rd Annual
Virtual Healthcare Conference and Evercore ISI 4th Annual
HealthCONx Conference on Monday, November 22, and Thursday,
December 2, respectively. (Photo: Business Wire)
Piper Sandler 33rd Annual Virtual Healthcare Conference
Presenters: George Farmer, Ph.D., Chief Financial Officer; Michael
Chen, Ph.D., Head of Innovation Date: Fireside chat available as of
10:00 AM EST on Monday, November 22, 2021
Evercore ISI 4th Annual HealthCONx Conference Presenters:
Daphne Zohar, Founder and CEO; Michael Chen, Ph.D., Head of
Innovation Date: Thursday, December 2, 2021 Time: 11:45 AM EST
About PureTech Health PureTech is a clinical-stage
biotherapeutics company dedicated to discovering, developing and
commercializing highly differentiated medicines for devastating
diseases, including inflammatory, fibrotic and immunological
conditions, intractable cancers, lymphatic and gastrointestinal
diseases and neurological and neuropsychological disorders, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech's Founded Entities, is comprised of 25
therapeutics and therapeutic candidates, including two that have
received both U.S. FDA clearance and European marketing
authorization, as of the date of PureTech's most recently filed
Half Year Report and corresponding Form 6-K. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements This
press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact, including those related to our participation at upcoming
investor conferences, should be considered forward-looking
statements. The forward-looking statements are based on current
expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual
results, performance and achievements to differ materially from
current expectations, including, but not limited to, those risks,
uncertainties and other important factors described under the
caption “Risk Factors” in our Annual Report on Form 20-F for the
year ended December 31, 2020 filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of
the Company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, we disclaim any obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211115005239/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. media Nichole Sarkis +1 774 278 8273
nichole@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024